207
Participants
Start Date
November 17, 2023
Primary Completion Date
March 31, 2025
Study Completion Date
April 11, 2025
Placebo
Study participants will receive placebo orally administered as tablet at pre-specified time points during the study.
UCB0022
Study participants will receive UCB0022 dose A or B orally administered as tablet at pre-specified time points during the Treatment Period.
Pd0060 50614, New York
Pd0060 50521, New York
Pd0060 50610, Newark
Pd0060 50143, Henrico
Pd0060 50534, Virginia Beach
Pd0060 50402, Crab Orchard
Pd0060 50612, Raleigh
Pd0060 50619, Rock Hill
Pd0060 50075, Augusta
Pd0060 50605, Port Orange
Pd0060 50600, Altamonte Springs
Pd0060 50647, DeLand
Pd0060 50585, Winter Park
Pd0060 50584, Hollywood
Pd0060 50582, Miami
Pd0060 50579, Miami
Pd0060 50449, Miami
Pd0060 50577, Doral
Pd0060 50580, Miami
Pd0060 50616, Aventura
Pd0060 50596, Boca Raton
Pd0060 50603, Tampa
Pd0060 50620, St. Petersburg
Pd0060 50597, Naples
Pd0060 50524, Bradenton
Pd0060 50591, Ocala
Pd0060 50076, Columbus
Pd0060 50527, Toledo
Pd0060 50622, Cleveland
Pd0060 50604, Dayton
Pd0060 50087, Centerville
Pd0060 50595, Indianapolis
Pd0060 50386, Farmington Hills
Pd0060 50545, East Lansing
Pd0060 50613, Grand Rapids
Pd0060 50319, Iowa City
Pd0060 50074, Kansas City
Pd0060 50608, Little Rock
Pd0060 50398, Tulsa
Pd0060 50568, San Antonio
Pd0060 50496, Round Rock
Pd0060 50598, Englewood
Pd0060 50537, Salt Lake City
Pd0060 50506, Phoenix
Pd0060 50590, Scottsdale
Pd0060 50587, Los Angeles
Pd0060 50589, Los Alamitos
Pd0060 50452, Pasadena
Pd0060 50601, Loma Linda
Pd0060 50519, Fountain Valley
Pd0060 50428, Fresno
Pd0060 50607, Portland
Pd0060 50440, Bellevue
Pd0060 50292, Kirkland
Pd0060 50419, Spokane
Pd0060 50628, New Haven
Pd0060 50561, Lexington
Pd0060 50615, Boston
Pd0060 50085, Boston
Pd0060 50627, North Dartmouth
Pd0060 50110, Ann Arbor
UCB Biopharma SRL
INDUSTRY